#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-5	Human	_
1-2	6-12	Plasma	_
1-3	13-17	BDNF	_
1-4	18-20	Is	_
1-5	21-31	Associated	_
1-6	32-36	With	_
1-7	37-56	Amygdala-Prefrontal	_
1-8	57-63	Cortex	_
1-9	64-74	Functional	_
1-10	75-87	Connectivity	_
1-11	88-91	and	_
1-12	92-99	Problem	_
1-13	100-108	Drinking	_
1-14	109-118	Behaviors	_
1-15	119-127	Abstract	_
1-16	128-138	Background	_
1-17	139-150	Preclinical	_
1-18	151-158	studies	_
1-19	159-166	suggest	_
1-20	167-171	that	_
1-21	172-181	decreased	_
1-22	182-188	levels	_
1-23	189-191	of	_
1-24	192-205	brain-derived	_
1-25	206-218	neurotrophic	_
1-26	219-225	factor	_
1-27	226-228	in	_
1-28	229-232	the	_
1-29	233-241	amygdala	_
1-30	242-246	play	_
1-31	247-248	a	_
1-32	249-253	role	_
1-33	254-256	in	_
1-34	257-264	anxiety	_
1-35	265-268	and	_
1-36	269-276	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseScale
1-37	277-280	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseScale
1-38	281-289	disorder	_
1-39	290-291	.	_

2-1	292-295	The	_
2-2	296-307	association	_
2-3	308-315	between	_
2-4	316-329	brain-derived	_
2-5	330-342	neurotrophic	_
2-6	343-349	factor	_
2-7	350-356	levels	_
2-8	357-360	and	_
2-9	361-369	amygdala	_
2-10	370-378	function	_
2-11	379-381	in	_
2-12	382-388	humans	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
2-13	389-393	with	_
2-14	394-401	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-15	402-405	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-16	406-414	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-17	415-417	is	_
2-18	418-423	still	_
2-19	424-431	unclear	_
2-20	432-433	,	_
2-21	434-442	although	_
2-22	443-455	neuroimaging	_
2-23	456-463	studies	_
2-24	464-468	have	_
2-25	469-473	also	_
2-26	474-484	implicated	_
2-27	485-488	the	_
2-28	489-497	amygdala	_
2-29	498-500	in	_
2-30	501-508	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-31	509-512	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-32	513-521	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-33	522-525	and	_
2-34	526-533	suggest	_
2-35	534-538	that	_
2-36	539-546	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-37	547-550	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-38	551-559	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-39	560-562	is	_
2-40	563-573	associated	_
2-41	574-578	with	_
2-42	579-588	disrupted	_
2-43	589-599	functional	_
2-44	600-612	connectivity	_
2-45	613-620	between	_
2-46	621-624	the	_
2-47	625-633	amygdala	_
2-48	634-637	and	_
2-49	638-648	prefrontal	_
2-50	649-655	cortex	_
2-51	656-662	during	_
2-52	663-671	aversive	_
2-53	672-678	states	_
2-54	679-680	.	_

3-1	681-688	Methods	_
3-2	689-692	The	_
3-3	693-700	current	_
3-4	701-706	study	_
3-5	707-719	investigated	_
3-6	720-727	whether	_
3-7	728-734	plasma	_
3-8	735-748	brain-derived	_
3-9	749-761	neurotrophic	_
3-10	762-768	factor	_
3-11	769-775	levels	_
3-12	776-778	in	_
3-13	779-790	individuals	_
3-14	791-795	with	_
3-15	796-799	and	_
3-16	800-807	without	_
3-17	808-815	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
3-18	816-819	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
3-19	820-828	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
3-20	829-830	(	_
3-21	831-832	n	_
3-22	833-834	=	_
3-23	835-837	57	_
3-24	838-839	)	_
3-25	840-844	were	_
3-26	845-855	associated	_
3-27	856-860	with	_
3-28	861-871	individual	_
3-29	872-883	differences	_
3-30	884-886	in	_
3-31	887-895	amygdala	_
3-32	896-906	reactivity	_
3-33	907-910	and	_
3-34	911-930	amygdala-prefrontal	_
3-35	931-937	cortex	_
3-36	938-948	functional	_
3-37	949-961	connectivity	_
3-38	962-968	during	_
3-39	969-970	2	_
3-40	971-976	forms	_
3-41	977-979	of	_
3-42	980-988	aversive	_
3-43	989-999	responding	_
3-44	1000-1008	captured	_
3-45	1009-1012	via	_
3-46	1013-1023	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-47	1024-1032	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-48	1033-1042	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-49	1043-1050	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-50	1051-1052	:	_
3-51	1053-1060	anxiety	_
3-52	1061-1069	elicited	_
3-53	1070-1072	by	_
3-54	1073-1086	unpredictable	_
3-55	1087-1093	threat	_
3-56	1094-1096	of	_
3-57	1097-1102	shock	_
3-58	1103-1106	and	_
3-59	1107-1111	fear	_
3-60	1112-1120	elicited	_
3-61	1121-1123	by	_
3-62	1124-1135	predictable	_
3-63	1136-1142	threat	_
3-64	1143-1145	of	_
3-65	1146-1151	shock	_
3-66	1152-1153	.	_

4-1	1154-1156	We	_
4-2	1157-1161	also	_
4-3	1162-1170	examined	_
4-4	1171-1178	whether	_
4-5	1179-1192	brain-derived	_
4-6	1193-1205	neurotrophic	_
4-7	1206-1212	factor	_
4-8	1213-1216	and	_
4-9	1217-1222	brain	_
4-10	1223-1231	function	_
4-11	1232-1236	were	_
4-12	1237-1247	associated	_
4-13	1248-1252	with	_
4-14	1253-1258	binge	_
4-15	1259-1267	drinking	_
4-16	1268-1276	episodes	_
4-17	1277-1280	and	_
4-18	1281-1288	alcohol	_
4-19	1289-1292	use	_
4-20	1293-1301	disorder	_
4-21	1302-1305	age	_
4-22	1306-1308	of	_
4-23	1309-1314	onset	_
4-24	1315-1316	.	_

5-1	1317-1324	Results	_
5-2	1325-1331	During	_
5-3	1332-1339	anxiety	_
5-4	1340-1341	,	_
5-5	1342-1345	but	_
5-6	1346-1349	not	_
5-7	1350-1354	fear	_
5-8	1355-1356	,	_
5-9	1357-1362	lower	_
5-10	1363-1369	levels	_
5-11	1370-1372	of	_
5-12	1373-1379	plasma	_
5-13	1380-1393	brain-derived	_
5-14	1394-1406	neurotrophic	_
5-15	1407-1413	factor	_
5-16	1414-1418	were	_
5-17	1419-1429	associated	_
5-18	1430-1434	with	_
5-19	1435-1439	less	_
5-20	1440-1452	connectivity	_
5-21	1453-1460	between	_
5-22	1461-1464	the	_
5-23	1465-1469	left	_
5-24	1470-1478	amygdala	_
5-25	1479-1482	and	_
5-26	1483-1486	the	_
5-27	1487-1493	medial	_
5-28	1494-1504	prefrontal	_
5-29	1505-1511	cortex	_
5-30	1512-1515	and	_
5-31	1516-1519	the	_
5-32	1520-1528	inferior	_
5-33	1529-1536	frontal	_
5-34	1537-1542	gyrus	_
5-35	1543-1544	.	_

6-1	1545-1547	In	_
6-2	1548-1556	addition	_
6-3	1557-1558	,	_
6-4	1559-1565	within	_
6-5	1566-1577	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
6-6	1578-1582	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
6-7	1583-1590	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
6-8	1591-1594	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
6-9	1595-1603	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
6-10	1604-1605	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
6-11	1606-1610	only	_
6-12	1611-1612	)	_
6-13	1613-1614	,	_
6-14	1615-1620	lower	_
6-15	1621-1627	levels	_
6-16	1628-1630	of	_
6-17	1631-1644	brain-derived	_
6-18	1645-1657	neurotrophic	_
6-19	1658-1664	factor	_
6-20	1665-1668	and	_
6-21	1669-1684	amygdala-medial	_
6-22	1685-1695	prefrontal	_
6-23	1696-1702	cortex	_
6-24	1703-1713	functional	_
6-25	1714-1726	connectivity	_
6-26	1727-1733	during	_
6-27	1734-1741	anxiety	_
6-28	1742-1746	were	_
6-29	1747-1757	associated	_
6-30	1758-1762	with	_
6-31	1763-1767	more	_
6-32	1768-1773	binge	_
6-33	1774-1782	episodes	_
6-34	1783-1789	within	_
6-35	1790-1793	the	_
6-36	1794-1798	past	_
6-37	1799-1801	60	_
6-38	1802-1806	days	_
6-39	1807-1810	and	_
6-40	1811-1812	a	_
6-41	1813-1818	lower	_
6-42	1819-1822	age	_
6-43	1823-1825	of	_
6-44	1826-1833	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
6-45	1834-1837	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
6-46	1838-1846	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
6-47	1847-1852	onset	_
6-48	1853-1854	.	_

7-1	1855-1860	There	_
7-2	1861-1865	were	_
7-3	1866-1868	no	_
7-4	1869-1881	associations	_
7-5	1882-1889	between	_
7-6	1890-1903	brain-derived	_
7-7	1904-1916	neurotrophic	_
7-8	1917-1923	factor	_
7-9	1924-1930	levels	_
7-10	1931-1934	and	_
7-11	1935-1940	focal	_
7-12	1941-1949	amygdala	_
7-13	1950-1954	task	_
7-14	1955-1965	reactivity	_
7-15	1966-1967	.	_

8-1	1968-1979	Conclusions	_
8-2	1980-1988	Together	_
8-3	1989-1990	,	_
8-4	1991-1994	the	_
8-5	1995-2002	results	_
8-6	2003-2011	indicate	_
8-7	2012-2016	that	_
8-8	2017-2023	plasma	_
8-9	2024-2037	brain-derived	_
8-10	2038-2050	neurotrophic	_
8-11	2051-2057	factor	_
8-12	2058-2064	levels	_
8-13	2065-2068	are	_
8-14	2069-2076	related	_
8-15	2077-2079	to	_
8-16	2080-2088	amygdala	_
8-17	2089-2096	circuit	_
8-18	2097-2108	functioning	_
8-19	2109-2111	in	_
8-20	2112-2118	humans	_
8-21	2119-2120	,	_
8-22	2121-2133	particularly	_
8-23	2134-2140	during	_
8-24	2141-2148	anxiety	_
8-25	2149-2150	,	_
8-26	2151-2154	and	_
8-27	2155-2160	these	_
8-28	2161-2171	individual	_
8-29	2172-2183	differences	_
8-30	2184-2187	may	_
8-31	2188-2194	relate	_
8-32	2195-2197	to	_
8-33	2198-2206	drinking	_
8-34	2207-2216	behaviors	_
8-35	2217-2218	.	_

9-1	2219-2226	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
9-2	2227-2239	Participants	_
9-3	2240-2250	Volunteers	_
9-4	2251-2255	were	_
9-5	2256-2265	recruited	_
9-6	2266-2269	via	_
9-7	2270-2284	advertisements	_
9-8	2285-2291	posted	_
9-9	2292-2294	in	_
9-10	2295-2298	the	_
9-11	2299-2306	Chicago	_
9-12	2307-2316	community	_
9-13	2317-2318	,	_
9-14	2319-2324	local	_
9-15	2325-2336	psychiatric	_
9-16	2337-2344	clinics	_
9-17	2345-2346	,	_
9-18	2347-2350	and	_
9-19	2351-2357	nearby	_
9-20	2358-2365	college	_
9-21	2366-2374	campuses	_
9-22	2375-2376	.	_

10-1	2377-2379	To	_
10-2	2380-2382	be	_
10-3	2383-2391	included	_
10-4	2392-2394	in	_
10-5	2395-2398	the	_
10-6	2399-2404	study	_
10-7	2405-2406	,	_
10-8	2407-2418	individuals	_
10-9	2419-2423	were	_
10-10	2424-2432	required	_
10-11	2433-2435	to	_
10-12	2436-2438	be	_
10-13	2439-2446	between	_
10-14	2447-2449	21	_
10-15	2450-2453	and	_
10-16	2454-2456	30	_
10-17	2457-2462	years	_
10-18	2463-2466	old	_
10-19	2467-2470	and	_
10-20	2471-2475	able	_
10-21	2476-2478	to	_
10-22	2479-2486	provide	_
10-23	2487-2494	written	_
10-24	2495-2503	informed	_
10-25	2504-2511	consent	_
10-26	2512-2513	.	_

11-1	2514-2525	Individuals	_
11-2	2526-2530	also	_
11-3	2531-2534	had	_
11-4	2535-2537	to	_
11-5	2538-2539	(	_
11-6	2540-2541	1	_
11-7	2542-2543	)	_
11-8	2544-2548	have	_
11-9	2549-2551	no	_
11-10	2552-2560	personal	_
11-11	2561-2563	or	_
11-12	2564-2570	family	_
11-13	2571-2578	history	_
11-14	2579-2581	of	_
11-15	2582-2585	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
11-16	2586-2587	(	_
11-17	2588-2592	i.e.	_
11-18	2593-2594	,	_
11-19	2595-2603	controls	_
11-20	2604-2605	)	_
11-21	2606-2608	or	_
11-22	2609-2610	(	_
11-23	2611-2612	2	_
11-24	2613-2614	)	_
11-25	2615-2619	meet	_
11-26	2620-2628	criteria	_
11-27	2629-2632	for	_
11-28	2633-2636	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
11-29	2637-2643	within	_
11-30	2644-2647	the	_
11-31	2648-2652	past	_
11-32	2653-2654	2	_
11-33	2655-2660	years	_
11-34	2661-2662	.	_

12-1	2663-2672	Exclusion	_
12-2	2673-2681	criteria	_
12-3	2682-2690	included	_
12-4	2691-2694	any	_
12-5	2695-2702	serious	_
12-6	2703-2710	medical	_
12-7	2711-2720	condition	_
12-8	2721-2722	,	_
12-9	2723-2735	psychotropic	_
12-10	2736-2746	medication	_
12-11	2747-2750	use	_
12-12	2751-2752	,	_
12-13	2753-2761	deafness	_
12-14	2762-2763	,	_
12-15	2764-2780	contraindication	_
12-16	2781-2784	for	_
12-17	2785-2797	neuroimaging	_
12-18	2798-2799	,	_
12-19	2800-2809	pregnancy	_
12-20	2810-2811	,	_
12-21	2812-2820	lifetime	_
12-22	2821-2829	moderate	_
12-23	2830-2832	or	_
12-24	2833-2839	severe	_
12-25	2840-2849	substance	_
12-26	2850-2853	use	_
12-27	2854-2862	disorder	_
12-28	2863-2864	(	_
12-29	2865-2870	other	_
12-30	2871-2875	than	_
12-31	2876-2883	alcohol	_
12-32	2884-2887	and	_
12-33	2888-2896	nicotine	_
12-34	2897-2898	)	_
12-35	2899-2900	,	_
12-36	2901-2906	daily	_
12-37	2907-2916	cigarette	_
12-38	2917-2924	smoking	_
12-39	2925-2926	,	_
12-40	2927-2930	and	_
12-41	2931-2940	psychosis	_
12-42	2941-2942	.	_

13-1	2943-2946	The	_
13-2	2947-2955	protocol	_
13-3	2956-2959	was	_
13-4	2960-2968	approved	_
13-5	2969-2971	by	_
13-6	2972-2975	the	_
13-7	2976-2986	university	_
13-8	2987-3000	institutional	_
13-9	3001-3007	review	_
13-10	3008-3013	board	_
13-11	3014-3017	and	_
13-12	3018-3030	participants	_
13-13	3031-3039	provided	_
13-14	3040-3047	written	_
13-15	3048-3056	informed	_
13-16	3057-3064	consent	_
13-17	3065-3066	.	_

14-1	3067-3078	Individuals	_
14-2	3079-3083	were	_
14-3	3084-3094	instructed	_
14-4	3095-3097	to	_
14-5	3098-3105	abstain	_
14-6	3106-3110	from	_
14-7	3111-3116	drugs	_
14-8	3117-3120	and	_
14-9	3121-3128	alcohol	_
14-10	3129-3131	24	_
14-11	3132-3137	hours	_
14-12	3138-3143	prior	_
14-13	3144-3146	to	_
14-14	3147-3150	the	_
14-15	3151-3161	laboratory	_
14-16	3162-3173	assessments	_
14-17	3174-3175	,	_
14-18	3176-3181	which	_
14-19	3182-3185	was	_
14-20	3186-3194	verified	_
14-21	3195-3198	via	_
14-22	3199-3205	breath	_
14-23	3206-3213	alcohol	_
14-24	3214-3217	and	_
14-25	3218-3223	urine	_
14-26	3224-3231	screens	_
14-27	3232-3233	.	_

15-1	3234-3246	Participants	_
15-2	3247-3251	were	_
15-3	3252-3262	monetarily	_
15-4	3263-3274	compensated	_
15-5	3275-3278	for	_
15-6	3279-3284	their	_
15-7	3285-3289	time	_
15-8	3290-3291	.	_

16-1	3292-3293	A	_
16-2	3294-3299	total	_
16-3	3300-3302	of	_
16-4	3303-3305	37	_
16-5	3306-3317	individuals	_
16-6	3318-3322	with	_
16-7	3323-3326	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
16-8	3327-3330	and	_
16-9	3331-3333	24	_
16-10	3334-3342	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-11	3343-3351	enrolled	_
16-12	3352-3354	in	_
16-13	3355-3358	the	_
16-14	3359-3364	study	_
16-15	3365-3368	and	_
16-16	3369-3378	completed	_
16-17	3379-3382	all	_
16-18	3383-3393	laboratory	_
16-19	3394-3404	procedures	_
16-20	3405-3406	(	_
16-21	3407-3412	total	_
16-22	3413-3414	n	_
16-23	3415-3416	=	_
16-24	3417-3419	61	_
16-25	3420-3421	)	_
16-26	3422-3423	.	_

17-1	3424-3425	A	_
17-2	3426-3431	total	_
17-3	3432-3434	of	_
17-4	3435-3436	4	_
17-5	3437-3448	individuals	_
17-6	3449-3452	had	_
17-7	3453-3462	excessive	_
17-8	3463-3469	motion	_
17-9	3470-3476	during	_
17-10	3477-3480	the	_
17-11	3481-3485	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
17-12	3486-3490	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
17-13	3491-3492	(	_
17-14	3493-3497	i.e.	_
17-15	3498-3499	,	_
17-16	3500-3501	<	_
17-17	3502-3508	2.5-mm	_
17-18	3509-3521	displacement	_
17-19	3522-3524	in	_
17-20	3525-3528	any	_
17-21	3529-3538	direction	_
17-22	3539-3540	)	_
17-23	3541-3544	and	_
17-24	3545-3549	were	_
17-25	3550-3558	excluded	_
17-26	3559-3563	from	_
17-27	3564-3572	analyses	_
17-28	3573-3574	(	_
17-29	3575-3576	3	_
17-30	3577-3580	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
17-31	3581-3589	subjects	_
17-32	3590-3593	and	_
17-33	3594-3595	1	_
17-34	3596-3603	control	_
17-35	3604-3605	)	_
17-36	3606-3609	for	_
17-37	3610-3611	a	_
17-38	3612-3617	final	_
17-39	3618-3624	sample	_
17-40	3625-3627	of	_
17-41	3628-3630	57	_
17-42	3631-3642	individuals	_
17-43	3643-3644	.	_

18-1	3645-3651	Please	_
18-2	3652-3655	see	_
18-3	3656-3661	Table	_
18-4	3662-3663	1	_
18-5	3664-3667	for	_
18-6	3668-3680	participants	_
18-7	3681-3682	’	_
18-8	3683-3695	demographics	_
18-9	3696-3699	and	_
18-10	3700-3708	clinical	_
18-11	3709-3724	characteristics	_
18-12	3725-3726	.	_

19-1	3727-3735	Clinical	_
19-2	3736-3747	Assessments	_
19-3	3748-3751	and	_
19-4	3752-3761	Procedure	_
19-5	3762-3774	Participants	_
19-6	3775-3784	completed	_
19-7	3785-3786	2	_
19-8	3787-3797	laboratory	_
19-9	3798-3804	visits	_
19-10	3805-3814	separated	_
19-11	3815-3817	by	_
19-12	3818-3821	1–7	_
19-13	3822-3826	days	_
19-14	3827-3828	.	_

20-1	3829-3832	The	_
20-2	3833-3838	first	_
20-3	3839-3844	visit	_
20-4	3845-3853	included	_
20-5	3854-3855	a	_
20-6	3856-3864	clinical	_
20-7	3865-3874	interview	_
20-8	3875-3876	,	_
20-9	3877-3878	a	_
20-10	3879-3886	battery	_
20-11	3887-3889	of	_
20-12	3890-3901	self-report	_
20-13	3902-3916	questionnaires	_
20-14	3917-3918	,	_
20-15	3919-3920	a	_
20-16	3921-3926	blood	_
20-17	3927-3931	draw	_
20-18	3932-3933	,	_
20-19	3934-3937	and	_
20-20	3938-3939	a	_
20-21	3940-3943	set	_
20-22	3944-3946	of	_
20-23	3947-3966	psychophysiological	_
20-24	3967-3972	tasks	_
20-25	3973-3974	.	_

21-1	3975-3978	The	_
21-2	3979-3985	second	_
21-3	3986-3991	visit	_
21-4	3992-4000	involved	_
21-5	4001-4005	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
21-6	4006-4010	data	_
21-7	4011-4021	collection	_
21-8	4022-4023	.	_

22-1	4024-4026	At	_
22-2	4027-4030	the	_
22-3	4031-4038	initial	_
22-4	4039-4046	session	_
22-5	4047-4048	,	_
22-6	4049-4057	lifetime	_
22-7	4058-4073	psychopathology	_
22-8	4074-4077	was	_
22-9	4078-4086	assessed	_
22-10	4087-4090	via	_
22-11	4091-4094	the	_
22-12	4095-4105	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-13	4106-4114	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-14	4115-4124	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-15	4125-4128	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-16	4129-4134	DSM-5	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-17	4135-4144	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-18	4145-4146	(	_
22-19	4147-4155	American	_
22-20	4156-4167	Psychiatric	_
22-21	4168-4179	Association	_
22-22	4180-4181	,	_
22-23	4182-4186	2015	_
22-24	4187-4188	)	_
22-25	4189-4190	,	_
22-26	4191-4200	in-person	_
22-27	4201-4202	,	_
22-28	4203-4205	by	_
22-29	4206-4213	trained	_
22-30	4214-4223	assessors	_
22-31	4224-4227	and	_
22-32	4228-4238	supervised	_
22-33	4239-4241	by	_
22-34	4242-4243	a	_
22-35	4244-4252	clinical	_
22-36	4253-4265	psychologist	_
22-37	4266-4267	.	_

23-1	4268-4271	Age	_
23-2	4272-4274	of	_
23-3	4275-4280	onset	_
23-4	4281-4283	of	_
23-5	4284-4287	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
23-6	4288-4291	was	_
23-7	4292-4300	recorded	_
23-8	4301-4307	during	_
23-9	4308-4311	the	_
23-10	4312-4322	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-11	4323-4331	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-12	4332-4341	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-13	4342-4345	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-14	4346-4351	DSM-5	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-15	4352-4361	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-16	4362-4371	interview	_
23-17	4372-4375	and	_
23-18	4376-4384	examined	_
23-19	4385-4387	in	_
23-20	4388-4391	the	_
23-21	4392-4399	current	_
23-22	4400-4405	study	_
23-23	4406-4411	given	_
23-24	4412-4416	that	_
23-25	4417-4422	lower	_
23-26	4423-4426	age	_
23-27	4427-4429	of	_
23-28	4430-4435	onset	_
23-29	4436-4438	is	_
23-30	4439-4449	associated	_
23-31	4450-4454	with	_
23-32	4455-4460	worse	_
23-33	4461-4464	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
23-34	4465-4474	prognosis	_
23-35	4475-4476	,	_
23-36	4477-4480	and	_
23-37	4481-4485	BDNF	_
23-38	4486-4496	expression	_
23-39	4497-4499	in	_
23-40	4500-4503	the	_
23-41	4504-4512	amygdala	_
23-42	4513-4515	is	_
23-43	4516-4525	decreased	_
23-44	4526-4528	in	_
23-45	4529-4540	individuals	_
23-46	4541-4545	with	_
23-47	4546-4551	early	_
23-48	4552-4553	,	_
23-49	4554-4557	but	_
23-50	4558-4561	not	_
23-51	4562-4566	late	_
23-52	4567-4568	,	_
23-53	4569-4572	AUD	http://maven.renci.org/NeuroBridge/neurobridge#DelayedOnsetPostTraumaticStressDisorder
23-54	4573-4578	onset	http://maven.renci.org/NeuroBridge/neurobridge#DelayedOnsetPostTraumaticStressDisorder
23-55	4579-4580	.	_

24-1	4581-4593	Participants	_
24-2	4594-4598	also	_
24-3	4599-4608	completed	_
24-4	4609-4610	a	_
24-5	4611-4619	detailed	_
24-6	4620-4630	assessment	_
24-7	4631-4633	of	_
24-8	4634-4639	their	_
24-9	4640-4646	recent	_
24-10	4647-4654	alcohol	_
24-11	4655-4658	use	_
24-12	4659-4668	employing	_
24-13	4669-4672	the	_
24-14	4673-4681	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-15	4682-4693	Follow-Back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-16	4694-4703	technique	_
24-17	4704-4705	(	_
24-18	4706-4712	Sobell	_
24-19	4713-4716	and	_
24-20	4717-4718	)	_
24-21	4719-4720	.	_

25-1	4721-4733	Participants	_
25-2	4734-4738	were	_
25-3	4739-4748	presented	_
25-4	4749-4753	with	_
25-5	4754-4755	a	_
25-6	4756-4764	calendar	_
25-7	4765-4767	of	_
25-8	4768-4771	the	_
25-9	4772-4776	past	_
25-10	4777-4779	60	_
25-11	4780-4784	days	_
25-12	4785-4786	,	_
25-13	4787-4793	marked	_
25-14	4794-4798	with	_
25-15	4799-4807	holidays	_
25-16	4808-4811	and	_
25-17	4812-4819	special	_
25-18	4820-4826	events	_
25-19	4827-4828	,	_
25-20	4829-4832	and	_
25-21	4833-4837	were	_
25-22	4838-4843	asked	_
25-23	4844-4846	to	_
25-24	4847-4855	indicate	_
25-25	4856-4858	on	_
25-26	4859-4863	what	_
25-27	4864-4868	days	_
25-28	4869-4873	they	_
25-29	4874-4879	drank	_
25-30	4880-4883	and	_
25-31	4884-4887	how	_
25-32	4888-4892	many	_
25-33	4893-4899	drinks	_
25-34	4900-4904	they	_
25-35	4905-4913	consumed	_
25-36	4914-4916	on	_
25-37	4917-4921	each	_
25-38	4922-4930	occasion	_
25-39	4931-4932	.	_

26-1	4933-4938	Using	_
26-2	4939-4942	the	_
26-3	4943-4951	Timeline	_
26-4	4952-4963	Follow-Back	_
26-5	4964-4973	technique	_
26-6	4974-4975	,	_
26-7	4976-4978	we	_
26-8	4979-4989	calculated	_
26-9	4990-4997	average	_
26-10	4998-5004	number	_
26-11	5005-5007	of	_
26-12	5008-5014	drinks	_
26-13	5015-5023	consumed	_
26-14	5024-5027	per	_
26-15	5028-5032	week	_
26-16	5033-5036	and	_
26-17	5037-5042	total	_
26-18	5043-5049	number	_
26-19	5050-5052	of	_
26-20	5053-5058	binge	_
26-21	5059-5067	episodes	_
26-22	5068-5072	over	_
26-23	5073-5076	the	_
26-24	5077-5081	past	_
26-25	5082-5084	60	_
26-26	5085-5089	days	_
26-27	5090-5091	.	_

27-1	5092-5097	Binge	_
27-2	5098-5106	episodes	_
27-3	5107-5111	were	_
27-4	5112-5119	defined	_
27-5	5120-5122	as	_
27-6	5123-5132	consuming	_
27-7	5133-5135	≥5	_
27-8	5136-5144	standard	_
27-9	5145-5151	drinks	_
27-10	5152-5155	for	_
27-11	5156-5159	men	_
27-12	5160-5163	and	_
27-13	5164-5166	≥4	_
27-14	5167-5173	drinks	_
27-15	5174-5177	for	_
27-16	5178-5183	women	_
27-17	5184-5186	in	_
27-18	5187-5188	1	_
27-19	5189-5196	sitting	_
27-20	5197-5198	.	_

28-1	5199-5204	Blood	_
28-2	5205-5215	Collection	http://maven.renci.org/NeuroBridge/neurobridge#Collection
28-3	5216-5219	and	_
28-4	5220-5224	BDNF	http://maven.renci.org/NeuroBridge/neurobridge#Thing
28-5	5225-5232	Protein	_
28-6	5233-5244	Measurement	http://maven.renci.org/NeuroBridge/neurobridge#SpectrophotometricMeasurement
28-7	5245-5249	Each	_
28-8	5250-5261	participant	_
28-9	5262-5270	provided	_
28-10	5271-5273	40	_
28-11	5274-5276	mL	_
28-12	5277-5279	of	_
28-13	5280-5285	whole	_
28-14	5286-5291	blood	_
28-15	5292-5293	,	_
28-16	5294-5299	which	_
28-17	5300-5303	was	_
28-18	5304-5313	collected	_
28-19	5314-5317	via	_
28-20	5318-5319	a	_
28-21	5320-5327	trained	_
28-22	5328-5340	phlebotomist	_
28-23	5341-5342	.	_

29-1	5343-5346	All	_
29-2	5347-5352	blood	_
29-3	5353-5358	draws	_
29-4	5359-5367	occurred	_
29-5	5368-5375	between	_
29-6	5376-5379	the	_
29-7	5380-5385	hours	_
29-8	5386-5388	of	_
29-9	5389-5391	10	_
29-10	5392-5394	am	_
29-11	5395-5398	and	_
29-12	5399-5400	1	_
29-13	5401-5403	pm	_
29-14	5404-5405	.	_

30-1	5406-5411	Blood	_
30-2	5412-5419	samples	_
30-3	5420-5424	were	_
30-4	5425-5434	collected	_
30-5	5435-5437	in	_
30-6	5438-5451	K2EDTA-coated	_
30-7	5452-5457	tubes	_
30-8	5458-5461	and	_
30-9	5462-5473	centrifuged	_
30-10	5474-5477	700	_
30-11	5478-5481	rpm	_
30-12	5482-5485	for	_
30-13	5486-5488	10	_
30-14	5489-5496	minutes	_
30-15	5497-5499	at	_
30-16	5500-5503	4°C	_
30-17	5504-5505	.	_

31-1	5506-5512	Plasma	_
31-2	5513-5524	supernatant	_
31-3	5525-5528	was	_
31-4	5529-5541	subsequently	_
31-5	5542-5553	transferred	_
31-6	5554-5556	to	_
31-7	5557-5558	a	_
31-8	5559-5564	clean	_
31-9	5565-5569	tube	_
31-10	5570-5573	and	_
31-11	5574-5585	immediately	_
31-12	5586-5592	frozen	_
31-13	5593-5595	at	_
31-14	5596-5601	−80°C	_
31-15	5602-5607	until	_
31-16	5608-5611	use	_
31-17	5612-5613	.	_

32-1	5614-5616	In	_
32-2	5617-5628	preparation	_
32-3	5629-5632	for	_
32-4	5633-5640	protein	_
32-5	5641-5652	measurement	_
32-6	5653-5654	,	_
32-7	5655-5661	plasma	_
32-8	5662-5669	samples	_
32-9	5670-5674	were	_
32-10	5675-5681	thawed	_
32-11	5682-5684	on	_
32-12	5685-5688	ice	_
32-13	5689-5690	,	_
32-14	5691-5700	clarified	_
32-15	5701-5704	via	_
32-16	5705-5706	a	_
32-17	5707-5716	20-minute	_
32-18	5717-5721	spin	_
32-19	5722-5724	at	_
32-20	5725-5727	10	_
32-21	5728-5731	000	_
32-22	5732-5733	g	_
32-23	5734-5736	at	_
32-24	5737-5740	4°C	_
32-25	5741-5744	for	_
32-26	5745-5753	complete	_
32-27	5754-5762	platelet	_
32-28	5763-5770	removal	_
32-29	5771-5772	,	_
32-30	5773-5776	and	_
32-31	5777-5788	supernatant	_
32-32	5789-5800	transferred	_
32-33	5801-5803	to	_
32-34	5804-5807	new	_
32-35	5808-5812	tube	_
32-36	5813-5814	.	_

33-1	5815-5819	BDNF	_
33-2	5820-5826	levels	_
33-3	5827-5831	were	_
33-4	5832-5843	ascertained	_
33-5	5844-5849	using	_
33-6	5850-5851	a	_
33-7	5852-5864	quantitative	_
33-8	5865-5867	in	_
33-9	5868-5873	vitro	_
33-10	5874-5887	enzyme-linked	_
33-11	5888-5901	immunosorbent	_
33-12	5902-5907	assay	_
33-13	5908-5911	kit	_
33-14	5912-5913	(	_
33-15	5914-5923	BioVision	_
33-16	5924-5925	,	_
33-17	5926-5934	Milpitas	_
33-18	5935-5936	,	_
33-19	5937-5939	CA	_
33-20	5940-5941	)	_
33-21	5942-5943	.	_

34-1	5944-5951	Briefly	_
34-2	5952-5953	,	_
34-3	5954-5957	100	_
34-4	5958-5960	µL	_
34-5	5961-5963	of	_
34-6	5964-5968	BDNF	_
34-7	5969-5978	standards	_
34-8	5979-5980	(	_
34-9	5981-5989	0.066–16	_
34-10	5990-5995	pg/uL	_
34-11	5996-6007	recombinant	_
34-12	6008-6013	human	_
34-13	6014-6018	BDNF	_
34-14	6019-6020	)	_
34-15	6021-6025	were	_
34-16	6026-6033	applied	_
34-17	6034-6036	in	_
34-18	6037-6046	duplicate	_
34-19	6047-6049	to	_
34-20	6050-6057	96-well	_
34-21	6058-6064	plates	_
34-22	6065-6074	precoated	_
34-23	6075-6079	with	_
34-24	6080-6082	an	_
34-25	6083-6091	antibody	_
34-26	6092-6100	specific	_
34-27	6101-6104	for	_
34-28	6105-6110	human	_
34-29	6111-6115	BDNF	_
34-30	6116-6117	.	_

35-1	6118-6121	The	_
35-2	6122-6129	samples	_
35-3	6130-6134	were	_
35-4	6135-6142	diluted	_
35-5	6143-6144	(	_
35-6	6145-6149	1:10	_
35-7	6150-6151	)	_
35-8	6152-6155	and	_
35-9	6156-6159	100	_
35-10	6160-6162	µL	_
35-11	6163-6166	was	_
35-12	6167-6172	added	_
35-13	6173-6175	to	_
35-14	6176-6179	the	_
35-15	6180-6185	plate	_
35-16	6186-6188	in	_
35-17	6189-6198	duplicate	_
35-18	6199-6200	.	_

36-1	6201-6204	The	_
36-2	6205-6210	plate	_
36-3	6211-6214	was	_
36-4	6215-6221	sealed	_
36-5	6222-6225	and	_
36-6	6226-6235	incubated	_
36-7	6236-6245	overnight	_
36-8	6246-6248	at	_
36-9	6249-6252	4°C	_
36-10	6253-6254	.	_

37-1	6255-6258	The	_
37-2	6259-6263	next	_
37-3	6264-6271	morning	_
37-4	6272-6273	,	_
37-5	6274-6277	the	_
37-6	6278-6283	plate	_
37-7	6284-6287	was	_
37-8	6288-6294	rinsed	_
37-9	6295-6299	with	_
37-10	6300-6311	wash-buffer	_
37-11	6312-6313	4	_
37-12	6314-6319	times	_
37-13	6320-6323	and	_
37-14	6324-6333	incubated	_
37-15	6334-6338	with	_
37-16	6339-6351	biotinylated	_
37-17	6352-6359	primary	_
37-18	6360-6369	antiserum	_
37-19	6370-6372	at	_
37-20	6373-6377	room	_
37-21	6378-6389	temperature	_
37-22	6390-6394	with	_
37-23	6395-6401	gentle	_
37-24	6402-6409	shaking	_
37-25	6410-6413	for	_
37-26	6414-6415	1	_
37-27	6416-6420	hour	_
37-28	6421-6422	.	_

38-1	6423-6428	Wells	_
38-2	6429-6433	were	_
38-3	6434-6440	washed	_
38-4	6441-6446	again	_
38-5	6447-6448	,	_
38-6	6449-6458	incubated	_
38-7	6459-6463	with	_
38-8	6464-6465	a	_
38-9	6466-6482	streptavidin-HRP	_
38-10	6483-6490	complex	_
38-11	6491-6494	for	_
38-12	6495-6497	45	_
38-13	6498-6505	minutes	_
38-14	6506-6509	and	_
38-15	6510-6519	developed	_
38-16	6520-6522	in	_
38-17	6523-6524	a	_
38-18	6525-6533	solution	_
38-19	6534-6536	of	_
38-20	6537-6557	tetramethylbenzidine	_
38-21	6558-6561	for	_
38-22	6562-6564	20	_
38-23	6565-6572	minutes	_
38-24	6573-6575	in	_
38-25	6576-6579	the	_
38-26	6580-6584	dark	_
38-27	6585-6590	prior	_
38-28	6591-6593	to	_
38-29	6594-6602	stopping	_
38-30	6603-6606	the	_
38-31	6607-6615	reaction	_
38-32	6616-6620	with	_
38-33	6621-6622	a	_
38-34	6623-6625	2N	_
38-35	6626-6634	sulfuric	_
38-36	6635-6639	acid	_
38-37	6640-6644	stop	_
38-38	6645-6653	solution	_
38-39	6654-6655	.	_

39-1	6656-6663	Samples	_
39-2	6664-6667	and	_
39-3	6668-6677	standards	_
39-4	6678-6682	were	_
39-5	6683-6686	run	_
39-6	6687-6689	in	_
39-7	6690-6699	duplicate	_
39-8	6700-6703	and	_
39-9	6704-6714	replicated	_
39-10	6715-6721	across	_
39-11	6722-6723	a	_
39-12	6724-6731	minimum	_
39-13	6732-6734	of	_
39-14	6735-6736	2	_
39-15	6737-6750	enzyme-linked	_
39-16	6751-6764	immunosorbent	_
39-17	6765-6771	assays	_
39-18	6772-6773	.	_

40-1	6774-6777	The	_
40-2	6778-6785	optical	_
40-3	6786-6793	density	_
40-4	6794-6796	of	_
40-5	6797-6801	each	_
40-6	6802-6808	sample	_
40-7	6809-6812	and	_
40-8	6813-6821	standard	_
40-9	6822-6825	was	_
40-10	6826-6834	measured	_
40-11	6835-6837	at	_
40-12	6838-6841	450	_
40-13	6842-6844	nm	_
40-14	6845-6850	using	_
40-15	6851-6854	the	_
40-16	6855-6862	Spectra	_
40-17	6863-6865	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-18	6866-6876	microplate	_
40-19	6877-6883	reader	_
40-20	6884-6885	(	_
40-21	6886-6891	Dynex	_
40-22	6892-6904	Technologies	_
40-23	6905-6906	,	_
40-24	6907-6916	Chantilly	_
40-25	6917-6918	,	_
40-26	6919-6921	VA	_
40-27	6922-6923	)	_
40-28	6924-6925	,	_
40-29	6926-6929	and	_
40-30	6930-6933	the	_
40-31	6934-6940	amount	_
40-32	6941-6943	of	_
40-33	6944-6948	BDNF	_
40-34	6949-6951	in	_
40-35	6952-6956	each	_
40-36	6957-6963	sample	_
40-37	6964-6967	was	_
40-38	6968-6978	calculated	_
40-39	6979-6986	against	_
40-40	6987-6990	the	_
40-41	6991-6995	BDNF	_
40-42	6996-7004	standard	_
40-43	7005-7010	curve	_
40-44	7011-7014	and	_
40-45	7015-7024	expressed	_
40-46	7025-7027	as	_
40-47	7028-7033	pg/uL	_
40-48	7034-7036	of	_
40-49	7037-7044	protein	_
40-50	7045-7046	.	_

41-1	7047-7051	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
41-2	7052-7058	Threat	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
41-3	7059-7063	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
41-4	7064-7069	Prior	_
41-5	7070-7072	to	_
41-6	7073-7076	the	_
41-7	7077-7081	task	_
41-8	7082-7083	,	_
41-9	7084-7094	electrodes	_
41-10	7095-7099	were	_
41-11	7100-7106	placed	_
41-12	7107-7109	on	_
41-13	7110-7122	participants	_
41-14	7123-7124	’	_
41-15	7125-7129	left	_
41-16	7130-7134	foot	_
41-17	7135-7138	and	_
41-18	7139-7140	a	_
41-19	7141-7146	shock	_
41-20	7147-7154	work-up	_
41-21	7155-7158	was	_
41-22	7159-7168	completed	_
41-23	7169-7171	to	_
41-24	7172-7180	identify	_
41-25	7181-7184	the	_
41-26	7185-7190	level	_
41-27	7191-7193	of	_
41-28	7194-7199	shock	_
41-29	7200-7209	intensity	_
41-30	7210-7214	each	_
41-31	7215-7226	participant	_
41-32	7227-7236	described	_
41-33	7237-7239	as	_
41-34	7240-7241	“	_
41-35	7242-7248	highly	_
41-36	7249-7257	annoying	_
41-37	7258-7261	but	_
41-38	7262-7265	not	_
41-39	7266-7273	painful	_
41-40	7274-7275	”	_
41-41	7276-7277	(	_
41-42	7278-7285	between	_
41-43	7286-7287	1	_
41-44	7288-7291	and	_
41-45	7292-7293	5	_
41-46	7294-7296	mA	_
41-47	7297-7298	)	_
41-48	7299-7300	.	_

42-1	7301-7304	The	_
42-2	7305-7309	task	_
42-3	7310-7313	was	_
42-4	7314-7322	designed	_
42-5	7323-7325	to	_
42-6	7326-7328	be	_
42-7	7329-7338	analogous	_
42-8	7339-7341	to	_
42-9	7342-7345	the	_
42-10	7346-7352	widely	_
42-11	7353-7357	used	_
42-12	7358-7368	NPU-threat	_
42-13	7369-7373	task	_
42-14	7374-7383	described	_
42-15	7384-7386	by	_
42-16	7387-7388	.	_

43-1	7389-7394	There	_
43-2	7395-7399	were	_
43-3	7400-7401	3	_
43-4	7402-7420	within-participant	_
43-5	7421-7431	conditions	_
43-6	7432-7433	:	_
43-7	7434-7435	N	_
43-8	7436-7437	,	_
43-9	7438-7439	P	_
43-10	7440-7445	shock	_
43-11	7446-7447	,	_
43-12	7448-7451	and	_
43-13	7452-7453	U	_
43-14	7454-7459	shock	_
43-15	7460-7461	.	_

44-1	7462-7468	During	_
44-2	7469-7473	each	_
44-3	7474-7483	condition	_
44-4	7484-7485	,	_
44-5	7486-7498	participants	_
44-6	7499-7505	viewed	_
44-7	7506-7507	a	_
44-8	7508-7515	numeric	_
44-9	7516-7525	countdown	_
44-10	7526-7530	that	_
44-11	7531-7537	ranged	_
44-12	7538-7545	between	_
44-13	7546-7547	3	_
44-14	7548-7551	and	_
44-15	7552-7553	8	_
44-16	7554-7561	seconds	_
44-17	7562-7563	(	_
44-18	7564-7565	M	_
44-19	7566-7567	=	_
44-20	7568-7569	5	_
44-21	7570-7577	seconds	_
44-22	7578-7579	)	_
44-23	7580-7581	.	_

45-1	7582-7586	Text	_
45-2	7587-7589	at	_
45-3	7590-7593	the	_
45-4	7594-7600	bottom	_
45-5	7601-7603	of	_
45-6	7604-7607	the	_
45-7	7608-7616	computer	_
45-8	7617-7624	monitor	_
45-9	7625-7633	informed	_
45-10	7634-7646	participants	_
45-11	7647-7649	of	_
45-12	7650-7653	the	_
45-13	7654-7661	current	_
45-14	7662-7671	condition	_
45-15	7672-7673	.	_

46-1	7674-7680	During	_
46-2	7681-7682	N	_
46-3	7683-7684	,	_
46-4	7685-7687	no	_
46-5	7688-7694	shocks	_
46-6	7695-7699	were	_
46-7	7700-7709	delivered	_
46-8	7710-7713	and	_
46-9	7714-7717	the	_
46-10	7718-7722	text	_
46-11	7723-7727	read	_
46-12	7728-7729	“	_
46-13	7730-7732	no	_
46-14	7733-7739	shock.	_
46-15	7740-7741	”	_
46-16	7742-7748	During	_
46-17	7749-7750	P	_
46-18	7751-7752	,	_
46-19	7753-7765	participants	_
46-20	7766-7774	received	_
46-21	7775-7776	a	_
46-22	7777-7782	shock	_
46-23	7783-7787	only	_
46-24	7788-7792	when	_
46-25	7793-7796	the	_
46-26	7797-7806	countdown	_
46-27	7807-7814	reached	_
46-28	7815-7816	“	_
46-29	7817-7818	1	_
46-30	7819-7820	”	_
46-31	7821-7824	and	_
46-32	7825-7828	the	_
46-33	7829-7833	text	_
46-34	7834-7838	read	_
46-35	7839-7840	“	_
46-36	7841-7846	shock	_
46-37	7847-7849	at	_
46-38	7850-7851	1	_
46-39	7852-7853	”	_
46-40	7854-7855	.	_

47-1	7856-7862	During	_
47-2	7863-7864	U	_
47-3	7865-7866	,	_
47-4	7867-7879	participants	_
47-5	7880-7888	received	_
47-6	7889-7890	a	_
47-7	7891-7896	shock	_
47-8	7897-7899	at	_
47-9	7900-7906	random	_
47-10	7907-7908	,	_
47-11	7909-7919	regardless	_
47-12	7920-7922	of	_
47-13	7923-7926	the	_
47-14	7927-7933	number	_
47-15	7934-7936	on	_
47-16	7937-7940	the	_
47-17	7941-7947	screen	_
47-18	7948-7951	and	_
47-19	7952-7955	the	_
47-20	7956-7960	text	_
47-21	7961-7965	read	_
47-22	7966-7967	“	_
47-23	7968-7973	shock	_
47-24	7974-7976	at	_
47-25	7977-7985	anytime.	_
47-26	7986-7987	”	_
47-27	7988-7997	Following	_
47-28	7998-8002	each	_
47-29	8003-8012	countdown	_
47-30	8013-8014	,	_
47-31	8015-8026	individuals	_
47-32	8027-8030	saw	_
47-33	8031-8032	a	_
47-34	8033-8041	fixation	_
47-35	8042-8047	cross	_
47-36	8048-8051	for	_
47-37	8052-8053	5	_
47-38	8054-8056	to	_
47-39	8057-8058	7	_
47-40	8059-8066	seconds	_
47-41	8067-8068	(	_
47-42	8069-8070	M	_
47-43	8071-8072	=	_
47-44	8073-8074	6	_
47-45	8075-8082	seconds	_
47-46	8083-8084	)	_
47-47	8085-8086	.	_

48-1	8087-8088	N	_
48-2	8089-8090	,	_
48-3	8091-8092	P	_
48-4	8093-8094	,	_
48-5	8095-8098	and	_
48-6	8099-8100	U	_
48-7	8101-8111	countdowns	_
48-8	8112-8116	were	_
48-9	8117-8126	presented	_
48-10	8127-8129	in	_
48-11	8130-8136	blocks	_
48-12	8137-8139	of	_
48-13	8140-8141	6	_
48-14	8142-8143	,	_
48-15	8144-8147	and	_
48-16	8148-8152	each	_
48-17	8153-8168	condition/block	_
48-18	8169-8172	was	_
48-19	8173-8185	administered	_
48-20	8186-8188	in	_
48-21	8189-8190	a	_
48-22	8191-8201	randomized	_
48-23	8202-8207	order	_
48-24	8208-8209	(	_
48-25	8210-8225	counterbalanced	_
48-26	8226-8227	)	_
48-27	8228-8229	6	_
48-28	8230-8235	times	_
48-29	8236-8240	over	_
48-30	8241-8244	the	_
48-31	8245-8251	course	_
48-32	8252-8254	of	_
48-33	8255-8256	2	_
48-34	8257-8261	runs	_
48-35	8262-8263	.	_

49-1	8264-8271	Notably	_
49-2	8272-8273	,	_
49-3	8274-8277	not	_
49-4	8278-8281	all	_
49-5	8282-8292	countdowns	_
49-6	8293-8296	ran	_
49-7	8297-8308	full-length	_
49-8	8309-8311	or	_
49-9	8312-8322	terminated	_
49-10	8323-8327	with	_
49-11	8328-8329	“	_
49-12	8330-8331	1	_
49-13	8332-8333	,	_
49-14	8334-8335	”	_
49-15	8336-8344	allowing	_
49-16	8345-8347	us	_
49-17	8348-8350	to	_
49-18	8351-8356	match	_
49-19	8357-8360	the	_
49-20	8361-8362	3	_
49-21	8363-8373	conditions	_
49-22	8374-8376	on	_
49-23	8377-8382	total	_
49-24	8383-8389	number	_
49-25	8390-8392	of	_
49-26	8393-8397	data	_
49-27	8398-8404	points	_
49-28	8405-8406	(	_
49-29	8407-8411	i.e.	_
49-30	8412-8413	,	_
49-31	8414-8428	TRs/repetition	_
49-32	8429-8434	times	_
49-33	8435-8436	)	_
49-34	8437-8438	.	_

50-1	8439-8451	Participants	_
50-2	8452-8460	received	_
50-3	8461-8463	10	_
50-4	8464-8472	electric	_
50-5	8473-8479	shocks	_
50-6	8480-8486	during	_
50-7	8487-8488	P	_
50-8	8489-8492	and	_
50-9	8493-8495	10	_
50-10	8496-8504	electric	_
50-11	8505-8511	shocks	_
50-12	8512-8518	during	_
50-13	8519-8520	U	_
50-14	8521-8527	during	_
50-15	8528-8532	each	_
50-16	8533-8536	run	_
50-17	8537-8538	.	_

51-1	8539-8542	The	_
51-2	8543-8547	rate	_
51-3	8548-8550	of	_
51-4	8551-8552	“	_
51-5	8553-8558	shock	_
51-6	8559-8561	at	_
51-7	8562-8563	1	_
51-8	8564-8565	”	_
51-9	8566-8572	during	_
51-10	8573-8576	the	_
51-11	8577-8578	P	_
51-12	8579-8588	condition	_
51-13	8589-8592	was	_
51-14	8593-8595	60	_
51-15	8596-8597	%	_
51-16	8598-8599	,	_
51-17	8600-8610	consistent	_
51-18	8611-8615	with	_
51-19	8616-8619	the	_
51-20	8620-8623	NPU	_
51-21	8624-8631	version	_
51-22	8632-8636	used	_
51-23	8637-8639	by	_
51-24	8640-8647	Grillon	_
51-25	8648-8651	and	_
51-26	8652-8662	colleagues	_
51-27	8663-8664	.	_

52-1	8665-8669	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
52-2	8670-8674	Data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
52-3	8675-8685	Collection	_
52-4	8686-8689	and	_
52-5	8690-8700	Processing	_
52-6	8701-8705	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
52-7	8706-8709	was	_
52-8	8710-8719	performed	_
52-9	8720-8722	on	_
52-10	8723-8724	a	_
52-11	8725-8728	3.0	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
52-12	8729-8734	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
52-13	8735-8737	GE	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
52-14	8738-8740	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
52-15	8741-8744	750	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
52-16	8745-8752	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
52-17	8753-8754	(	_
52-18	8755-8762	General	_
52-19	8763-8771	Electric	_
52-20	8772-8782	Healthcare	_
52-21	8783-8784	,	_
52-22	8785-8793	Waukesha	_
52-23	8794-8795	,	_
52-24	8796-8798	WI	_
52-25	8799-8800	)	_
52-26	8801-8806	using	_
52-27	8807-8809	an	_
52-28	8810-8819	8-channel	_
52-29	8820-8832	phased-array	_
52-30	8833-8838	radio	_
52-31	8839-8848	frequency	_
52-32	8849-8853	head	_
52-33	8854-8858	coil	_
52-34	8859-8860	.	_

53-1	8861-8862	A	_
53-2	8863-8871	standard	_
53-3	8872-8884	T2-sensitive	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
53-4	8885-8898	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
53-5	8899-8909	echoplanar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
53-6	8910-8917	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
53-7	8918-8926	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
53-8	8927-8930	was	_
53-9	8931-8935	used	_
53-10	8936-8937	(	_
53-11	8938-8939	2	_
53-12	8940-8947	seconds	_
53-13	8948-8950	TR	_
53-14	8951-8952	;	_
53-15	8953-8957	22.2	_
53-16	8958-8970	milliseconds	_
53-17	8971-8973	TE	_
53-18	8974-8975	;	_
53-19	8976-8979	90°	_
53-20	8980-8984	flip	_
53-21	8985-8986	;	_
53-22	8987-8989	64	_
53-23	8990-8991	×	_
53-24	8992-8994	64	_
53-25	8995-9001	matrix	_
53-26	9002-9003	;	_
53-27	9004-9006	22	_
53-28	9007-9009	cm	_
53-29	9010-9013	FOV	_
53-30	9014-9015	;	_
53-31	9016-9018	44	_
53-32	9019-9024	axial	_
53-33	9025-9031	slices	_
53-34	9032-9033	;	_
53-35	9034-9038	3.44	_
53-36	9039-9040	×	_
53-37	9041-9045	3.44	_
53-38	9046-9047	×	_
53-39	9048-9051	3.0	_
53-40	9052-9054	mm	_
53-41	9055-9061	voxels	_
53-42	9062-9063	;	_
53-43	9064-9067	336	_
53-44	9068-9075	volumes	_
53-45	9076-9077	)	_
53-46	9078-9079	.	_

54-1	9080-9083	All	_
54-2	9084-9088	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
54-3	9089-9093	data	_
54-4	9094-9097	met	_
54-5	9098-9106	criteria	_
54-6	9107-9110	for	_
54-7	9111-9115	high	_
54-8	9116-9123	quality	_
54-9	9124-9127	and	_
54-10	9128-9132	scan	_
54-11	9133-9142	stability	_
54-12	9143-9147	with	_
54-13	9148-9155	minimum	_
54-14	9156-9162	motion	_
54-15	9163-9173	correction	_
54-16	9174-9175	(	_
54-17	9176-9180	i.e.	_
54-18	9181-9182	,	_
54-19	9183-9184	<	_
54-20	9185-9186	2	_
54-21	9187-9189	mm	_
54-22	9190-9202	displacement	_
54-23	9203-9205	in	_
54-24	9206-9209	any	_
54-25	9210-9219	direction	_
54-26	9220-9221	)	_
54-27	9222-9223	.	_

55-1	9224-9237	Preprocessing	_
55-2	9238-9240	of	_
55-3	9241-9245	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
55-4	9246-9250	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
55-5	9251-9254	was	_
55-6	9255-9264	conducted	_
55-7	9265-9270	using	_
55-8	9271-9282	Statistical	_
55-9	9283-9293	Parametric	_
55-10	9294-9301	Mapping	_
55-11	9302-9310	software	_
55-12	9311-9312	(	_
55-13	9313-9318	SPM12	_
55-14	9319-9320	,	_
55-15	9321-9329	Wellcome	_
55-16	9330-9340	Department	_
55-17	9341-9343	of	_
55-18	9344-9351	Imaging	_
55-19	9352-9365	Neuro-Science	_
55-20	9366-9367	,	_
55-21	9368-9374	London	_
55-22	9375-9376	,	_
55-23	9377-9379	UK	_
55-24	9380-9381	)	_
55-25	9382-9383	,	_
55-26	9384-9387	and	_
55-27	9388-9389	,	_
55-28	9390-9401	accordingly	_
55-29	9402-9403	,	_
55-30	9404-9406	we	_
55-31	9407-9415	followed	_
55-32	9416-9419	the	_
55-33	9420-9428	standard	_
55-34	9429-9442	preprocessing	_
55-35	9443-9451	routines	_
55-36	9452-9461	suggested	_
55-37	9462-9464	by	_
55-38	9465-9468	SPM	_
55-39	9469-9470	.	_

56-1	9471-9474	The	_
56-2	9475-9480	first	_
56-3	9481-9482	4	_
56-4	9483-9490	volumes	_
56-5	9491-9495	were	_
56-6	9496-9505	discarded	_
56-7	9506-9508	to	_
56-8	9509-9514	allow	_
56-9	9515-9518	for	_
56-10	9519-9521	T1	_
56-11	9522-9535	equilibration	_
56-12	9536-9543	effects	_
56-13	9544-9545	.	_

57-1	9546-9552	Images	_
57-2	9553-9557	were	_
57-3	9558-9563	slice	_
57-4	9564-9568	time	_
57-5	9569-9578	corrected	_
57-6	9579-9583	with	_
57-7	9584-9587	the	_
57-8	9588-9597	reference	_
57-9	9598-9603	slice	_
57-10	9604-9609	based	_
57-11	9610-9612	on	_
57-12	9613-9616	the	_
57-13	9617-9623	middle	_
57-14	9624-9626	of	_
57-15	9627-9631	each	_
57-16	9632-9634	TR	_
57-17	9635-9636	,	_
57-18	9637-9646	realigned	_
57-19	9647-9651	with	_
57-20	9652-9655	the	_
57-21	9656-9661	first	_
57-22	9662-9668	volume	_
57-23	9669-9671	to	_
57-24	9672-9679	correct	_
57-25	9680-9683	for	_
57-26	9684-9688	head	_
57-27	9689-9695	motion	_
57-28	9696-9697	,	_
57-29	9698-9711	co-registered	_
57-30	9712-9714	to	_
57-31	9715-9718	the	_
57-32	9719-9731	participants	_
57-33	9732-9733	’	_
57-34	9734-9745	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
57-35	9746-9751	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
57-36	9752-9754	in	_
57-37	9755-9763	Montreal	_
57-38	9764-9776	Neurological	_
57-39	9777-9786	Institute	_
57-40	9787-9788	(	_
57-41	9789-9792	MNI	_
57-42	9793-9794	)	_
57-43	9795-9800	space	_
57-44	9801-9802	,	_
57-45	9803-9813	re-sampled	_
57-46	9814-9816	to	_
57-47	9817-9822	2-mm3	_
57-48	9823-9829	voxels	_
57-49	9830-9831	,	_
57-50	9832-9835	and	_
57-51	9836-9844	smoothed	_
57-52	9845-9850	using	_
57-53	9851-9852	a	_
57-54	9853-9857	8-mm	_
57-55	9858-9867	isotropic	_
57-56	9868-9876	Gaussian	_
57-57	9877-9883	kernel	_
57-58	9884-9885	.	_

58-1	9886-9889	The	_
58-2	9890-9897	general	_
58-3	9898-9904	linear	_
58-4	9905-9910	model	_
58-5	9911-9914	was	_
58-6	9915-9922	applied	_
58-7	9923-9925	to	_
58-8	9926-9929	the	_
58-9	9930-9934	time	_
58-10	9935-9941	series	_
58-11	9942-9943	,	_
58-12	9944-9953	convolved	_
58-13	9954-9958	with	_
58-14	9959-9962	the	_
58-15	9963-9972	canonical	_
58-16	9973-9984	hemodynamic	_
58-17	9985-9993	response	_
58-18	9994-10002	function	_
58-19	10003-10006	and	_
58-20	10007-10011	with	_
58-21	10012-10013	a	_
58-22	10014-10024	128-second	_
58-23	10025-10034	high-pass	_
58-24	10035-10041	filter	_
58-25	10042-10043	.	_

59-1	10044-10053	Condition	_
59-2	10054-10061	effects	_
59-3	10062-10065	for	_
59-4	10066-10067	U	_
59-5	10068-10069	,	_
59-6	10070-10071	P	_
59-7	10072-10073	,	_
59-8	10074-10077	and	_
59-9	10078-10079	N	_
59-10	10080-10092	anticipation	_
59-11	10093-10097	were	_
59-12	10098-10108	separately	_
59-13	10109-10118	estimated	_
59-14	10119-10121	at	_
59-15	10122-10126	each	_
59-16	10127-10132	voxel	_
59-17	10133-10136	for	_
59-18	10137-10141	each	_
59-19	10142-10153	participant	_
59-20	10154-10155	.	_

60-1	10156-10159	For	_
60-2	10160-10164	each	_
60-3	10165-10174	condition	_
60-4	10175-10176	,	_
60-5	10177-10180	the	_
60-6	10181-10191	countdowns	_
60-7	10192-10197	prior	_
60-8	10198-10200	to	_
60-9	10201-10204	the	_
60-10	10205-10210	shock	_
60-11	10211-10212	,	_
60-12	10213-10215	or	_
60-13	10216-10221	prior	_
60-14	10222-10224	to	_
60-15	10225-10230	trial	_
60-16	10231-10242	termination	_
60-17	10243-10245	in	_
60-18	10246-10255	instances	_
60-19	10256-10261	where	_
60-20	10262-10267	there	_
60-21	10268-10271	was	_
60-22	10272-10274	no	_
60-23	10275-10280	shock	_
60-24	10281-10282	,	_
60-25	10283-10287	were	_
60-26	10288-10295	modeled	_
60-27	10296-10297	.	_

61-1	10298-10300	Of	_
61-2	10301-10305	note	_
61-3	10306-10307	,	_
61-4	10308-10310	we	_
61-5	10311-10320	conducted	_
61-6	10321-10323	an	_
61-7	10324-10334	additional	_
61-8	10335-10338	set	_
61-9	10339-10341	of	_
61-10	10342-10350	analyses	_
61-11	10351-10356	where	_
61-12	10357-10360	the	_
61-13	10361-10363	U-	_
61-14	10364-10367	and	_
61-15	10368-10376	P-shocks	_
61-16	10377-10381	were	_
61-17	10382-10390	included	_
61-18	10391-10393	as	_
61-19	10394-10404	regressors	_
61-20	10405-10407	in	_
61-21	10408-10411	the	_
61-22	10412-10417	first	_
61-23	10418-10423	level	_
61-24	10424-10429	model	_
61-25	10430-10431	.	_

62-1	10432-10435	The	_
62-2	10436-10443	results	_
62-3	10444-10446	of	_
62-4	10447-10450	the	_
62-5	10451-10456	paper	_
62-6	10457-10461	were	_
62-7	10462-10472	consistent	_
62-8	10473-10480	whether	_
62-9	10481-10487	shocks	_
62-10	10488-10492	were	_
62-11	10493-10501	included	_
62-12	10502-10504	or	_
62-13	10505-10513	excluded	_
62-14	10514-10518	from	_
62-15	10519-10522	the	_
62-16	10523-10528	model	_
62-17	10529-10530	.	_

63-1	10531-10539	Movement	_
63-2	10540-10550	parameters	_
63-3	10551-10559	obtained	_
63-4	10560-10566	during	_
63-5	10567-10578	realignment	_
63-6	10579-10583	were	_
63-7	10584-10592	included	_
63-8	10593-10595	in	_
63-9	10596-10599	the	_
63-10	10600-10605	model	_
63-11	10606-10608	as	_
63-12	10609-10619	regressors	_
63-13	10620-10622	of	_
63-14	10623-10625	no	_
63-15	10626-10634	interest	_
63-16	10635-10637	to	_
63-17	10638-10645	account	_
63-18	10646-10649	for	_
63-19	10650-10664	motion-related	_
63-20	10665-10672	effects	_
63-21	10673-10675	on	_
63-22	10676-10680	BOLD	_
63-23	10681-10682	.	_

64-1	10683-10693	Individual	_
64-2	10694-10702	contrast	_
64-3	10703-10707	maps	_
64-4	10708-10711	for	_
64-5	10712-10720	U-threat	_
64-6	10721-10722	>	_
64-7	10723-10732	no-threat	_
64-8	10733-10734	(	_
64-9	10735-10739	i.e.	_
64-10	10740-10741	,	_
64-11	10742-10754	anticipatory	_
64-12	10755-10762	anxiety	_
64-13	10763-10764	)	_
64-14	10765-10768	and	_
64-15	10769-10777	P-threat	_
64-16	10778-10779	>	_
64-17	10780-10789	no-threat	_
64-18	10790-10791	(	_
64-19	10792-10796	i.e.	_
64-20	10797-10798	,	_
64-21	10799-10803	fear	_
64-22	10804-10805	)	_
64-23	10806-10810	were	_
64-24	10811-10818	created	_
64-25	10819-10822	for	_
64-26	10823-10827	each	_
64-27	10828-10839	participant	_
64-28	10840-10841	.	_

65-1	10842-10845	For	_
65-2	10846-10856	functional	_
65-3	10857-10869	connectivity	_
65-4	10870-10871	,	_
65-5	10872-10874	we	_
65-6	10875-10879	used	_
65-7	10880-10881	a	_
65-8	10882-10892	seed-based	_
65-9	10893-10894	,	_
65-10	10895-10906	generalized	_
65-11	10907-10911	form	_
65-12	10912-10914	of	_
65-13	10915-10932	context-dependent	_
65-14	10933-10952	psychophysiological	_
65-15	10953-10964	interaction	_
65-16	10965-10966	(	_
65-17	10967-10970	PPI	_
65-18	10971-10972	)	_
65-19	10973-10981	analyses	_
65-20	10982-10983	(	_
65-21	10984-10988	http	_
65-22	10989-10990	:	_
65-23	10991-11014	//brainmap.wisc.edu/PPI	_
65-24	11015-11016	,	_
65-25	11017-11018	)	_
65-26	11019-11020	,	_
65-27	11021-11025	with	_
65-28	11026-11030	left	_
65-29	11031-11034	and	_
65-30	11035-11040	right	_
65-31	11041-11051	anatomical	_
65-32	11052-11060	amygdala	_
65-33	11061-11066	masks	_
65-34	11067-11068	(	_
65-35	11069-11076	created	_
65-36	11077-11082	using	_
65-37	11083-11086	AAL	_
65-38	11087-11092	atlas	_
65-39	11093-11094	)	_
65-40	11095-11097	as	_
65-41	11098-11101	the	_
65-42	11102-11107	seeds	_
65-43	11108-11110	of	_
65-44	11111-11119	interest	_
65-45	11120-11121	.	_

66-1	11122-11125	The	_
66-2	11126-11138	de-convolved	_
66-3	11139-11143	time	_
66-4	11144-11150	series	_
66-5	11151-11155	from	_
66-6	11156-11159	the	_
66-7	11160-11168	amygdala	_
66-8	11169-11174	masks	_
66-9	11175-11179	were	_
66-10	11180-11189	extracted	_
66-11	11190-11193	for	_
66-12	11194-11198	each	_
66-13	11199-11210	participant	_
66-14	11211-11213	to	_
66-15	11214-11220	create	_
66-16	11221-11224	the	_
66-17	11225-11238	physiological	_
66-18	11239-11248	variables	_
66-19	11249-11250	.	_

67-1	11251-11254	The	_
67-2	11255-11264	condition	_
67-3	11265-11270	onset	_
67-4	11271-11276	times	_
67-5	11277-11280	for	_
67-6	11281-11289	U-threat	_
67-7	11290-11291	,	_
67-8	11292-11300	P-threat	_
67-9	11301-11302	,	_
67-10	11303-11306	and	_
67-11	11307-11316	no-threat	_
67-12	11317-11321	were	_
67-13	11322-11332	separately	_
67-14	11333-11342	convolved	_
67-15	11343-11347	with	_
67-16	11348-11351	the	_
67-17	11352-11361	canonical	_
67-18	11362-11373	hemodynamic	_
67-19	11374-11382	response	_
67-20	11383-11391	function	_
67-21	11392-11393	(	_
67-22	11394-11397	HRF	_
67-23	11398-11399	)	_
67-24	11400-11403	for	_
67-25	11404-11408	each	_
67-26	11409-11418	condition	_
67-27	11419-11420	,	_
67-28	11421-11429	creating	_
67-29	11430-11433	the	_
67-30	11434-11447	psychological	_
67-31	11448-11458	regressors	_
67-32	11459-11460	.	_

68-1	11461-11464	The	_
68-2	11465-11476	interaction	_
68-3	11477-11482	terms	_
68-4	11483-11484	(	_
68-5	11485-11489	PPIs	_
68-6	11490-11491	)	_
68-7	11492-11496	were	_
68-8	11497-11505	computed	_
68-9	11506-11508	by	_
68-10	11509-11520	multiplying	_
68-11	11521-11524	the	_
68-12	11525-11529	time	_
68-13	11530-11536	series	_
68-14	11537-11541	from	_
68-15	11542-11545	the	_
68-16	11546-11559	psychological	_
68-17	11560-11570	regressors	_
68-18	11571-11575	with	_
68-19	11576-11579	the	_
68-20	11580-11593	physiological	_
68-21	11594-11602	variable	_
68-22	11603-11604	.	_

69-1	11605-11613	Activity	_
69-2	11614-11620	within	_
69-3	11621-11624	the	_
69-4	11625-11633	amygdala	_
69-5	11634-11637	was	_
69-6	11638-11642	then	_
69-7	11643-11652	regressed	_
69-8	11653-11655	on	_
69-9	11656-11657	a	_
69-10	11658-11668	voxel-wise	_
69-11	11669-11674	basis	_
69-12	11675-11682	against	_
69-13	11683-11686	the	_
69-14	11687-11698	interaction	_
69-15	11699-11700	,	_
69-16	11701-11705	with	_
69-17	11706-11709	the	_
69-18	11710-11723	physiological	_
69-19	11724-11727	and	_
69-20	11728-11741	psychological	_
69-21	11742-11751	variables	_
69-22	11752-11759	serving	_
69-23	11760-11762	as	_
69-24	11763-11773	regressors	_
69-25	11774-11776	of	_
69-26	11777-11785	interest	_
69-27	11786-11787	.	_

70-1	11788-11798	Individual	_
70-2	11799-11807	U-threat	_
70-3	11808-11809	>	_
70-4	11810-11819	no-threat	_
70-5	11820-11823	and	_
70-6	11824-11832	P-threat	_
70-7	11833-11834	>	_
70-8	11835-11844	no-threat	_
70-9	11845-11848	PPI	_
70-10	11849-11855	images	_
70-11	11856-11860	were	_
70-12	11861-11868	created	_
70-13	11869-11872	for	_
70-14	11873-11878	every	_
70-15	11879-11890	participant	_
70-16	11891-11892	.	_

71-1	11893-11897	Data	_
71-2	11898-11906	Analysis	_
71-3	11907-11911	Plan	_
71-4	11912-11914	To	_
71-5	11915-11922	examine	_
71-6	11923-11930	whether	_
71-7	11931-11935	BDNF	_
71-8	11936-11939	was	_
71-9	11940-11950	associated	_
71-10	11951-11955	with	_
71-11	11956-11964	amygdala	_
71-12	11965-11975	reactivity	_
71-13	11976-11977	,	_
71-14	11978-11980	we	_
71-15	11981-11985	used	_
71-16	11986-11987	a	_
71-17	11988-11995	focused	_
71-18	11996-11997	,	_
71-19	11998-12016	region-of-interest	_
71-20	12017-12025	analysis	_
71-21	12026-12034	approach	_
71-22	12035-12036	.	_

72-1	12037-12039	We	_
72-2	12040-12047	entered	_
72-3	12048-12051	the	_
72-4	12052-12060	U-threat	_
72-5	12061-12062	>	_
72-6	12063-12072	no-threat	_
72-7	12073-12076	and	_
72-8	12077-12085	P-threat	_
72-9	12086-12087	>	_
72-10	12088-12097	no-threat	_
72-11	12098-12104	images	_
72-12	12105-12109	into	_
72-13	12110-12118	separate	_
72-14	12119-12127	1-sample	_
72-15	12128-12129	t	_
72-16	12130-12135	tests	_
72-17	12136-12137	.	_

73-1	12138-12142	Then	_
73-2	12143-12145	we	_
73-3	12146-12155	extracted	_
73-4	12156-12160	mean	_
73-5	12161-12165	task	_
73-6	12166-12176	activation	_
73-7	12177-12186	parameter	_
73-8	12187-12196	estimates	_
73-9	12197-12198	(	_
73-10	12199-12208	β-weights	_
73-11	12209-12210	;	_
73-12	12211-12220	arbitrary	_
73-13	12221-12225	unit	_
73-14	12226-12227	)	_
73-15	12228-12232	from	_
73-16	12233-12241	separate	_
73-17	12242-12246	left	_
73-18	12247-12250	and	_
73-19	12251-12256	right	_
73-20	12257-12262	whole	_
73-21	12263-12273	anatomical	_
73-22	12274-12282	amygdala	_
73-23	12283-12288	masks	_
73-24	12289-12290	(	_
73-25	12291-12298	created	_
73-26	12299-12304	using	_
73-27	12305-12308	AAL	_
73-28	12309-12314	atlas	_
73-29	12315-12316	)	_
73-30	12317-12321	from	_
73-31	12322-12326	each	_
73-32	12327-12332	model	_
73-33	12333-12334	(	_
73-34	12335-12343	U-threat	_
73-35	12344-12347	and	_
73-36	12348-12356	P-threat	_
73-37	12357-12358	)	_
73-38	12359-12360	.	_

74-1	12361-12366	Using	_
74-2	12367-12374	Pearson	_
74-3	12375-12376	’	_
74-4	12377-12378	s	_
74-5	12379-12391	correlations	_
74-6	12392-12393	,	_
74-7	12394-12396	we	_
74-8	12397-12405	assessed	_
74-9	12406-12413	whether	_
74-10	12414-12420	plasma	_
74-11	12421-12425	BDNF	_
74-12	12426-12432	levels	_
74-13	12433-12437	were	_
74-14	12438-12448	associated	_
74-15	12449-12453	with	_
74-16	12454-12459	focal	_
74-17	12460-12464	left	_
74-18	12465-12468	and	_
74-19	12469-12474	right	_
74-20	12475-12483	amygdala	_
74-21	12484-12494	reactivity	_
74-22	12495-12501	during	_
74-23	12502-12510	U-threat	_
74-24	12511-12514	and	_
74-25	12515-12523	P-threat	_
74-26	12524-12525	.	_

75-1	12526-12528	To	_
75-2	12529-12536	examine	_
75-3	12537-12540	the	_
75-4	12541-12547	impact	_
75-5	12548-12550	of	_
75-6	12551-12555	BDNF	_
75-7	12556-12558	on	_
75-8	12559-12571	amygdala-PFC	_
75-9	12572-12582	functional	_
75-10	12583-12595	connectivity	_
75-11	12596-12597	,	_
75-12	12598-12601	the	_
75-13	12602-12610	U-threat	_
75-14	12611-12612	>	_
75-15	12613-12622	no-threat	_
75-16	12623-12626	and	_
75-17	12627-12635	P-threat	_
75-18	12636-12637	>	_
75-19	12638-12647	no-threat	_
75-20	12648-12654	images	_
75-21	12655-12659	were	_
75-22	12660-12667	entered	_
75-23	12668-12672	into	_
75-24	12673-12674	2	_
75-25	12675-12683	separate	_
75-26	12684-12693	2nd-level	_
75-27	12694-12702	1-sample	_
75-28	12703-12704	t	_
75-29	12705-12710	tests	_
75-30	12711-12715	with	_
75-31	12716-12726	individual	_
75-32	12727-12731	BDNF	_
75-33	12732-12738	values	_
75-34	12739-12741	as	_
75-35	12742-12743	a	_
75-36	12744-12753	regressor	_
75-37	12754-12755	.	_

76-1	12756-12758	To	_
76-2	12759-12768	determine	_
76-3	12769-12772	our	_
76-4	12773-12777	fMRI	_
76-5	12778-12790	significance	_
76-6	12791-12800	threshold	_
76-7	12801-12802	,	_
76-8	12803-12805	we	_
76-9	12806-12813	applied	_
76-10	12814-12816	an	_
76-11	12817-12829	anatomically	_
76-12	12830-12837	derived	_
76-13	12838-12839	(	_
76-14	12840-12843	AAL	_
76-15	12844-12849	atlas	_
76-16	12850-12851	)	_
76-17	12852-12859	partial	_
76-18	12860-12865	brain	_
76-19	12866-12870	mask	_
76-20	12871-12873	of	_
76-21	12874-12877	the	_
76-22	12878-12884	entire	_
76-23	12885-12888	PFC	_
76-24	12889-12891	to	_
76-25	12892-12895	our	_
76-26	12896-12900	data	_
76-27	12901-12902	(	_
76-28	12903-12909	search	_
76-29	12910-12916	volume	_
76-30	12917-12918	=	_
76-31	12919-12922	451	_
76-32	12923-12926	840	_
76-33	12927-12930	mm3	_
76-34	12931-12932	,	_
76-35	12933-12945	encompassing	_
76-36	12946-12948	56	_
76-37	12949-12952	480	_
76-38	12953-12959	voxels	_
76-39	12960-12961	)	_
76-40	12962-12963	.	_

77-1	12964-12967	The	_
77-2	12968-12974	search	_
77-3	12975-12978	for	_
77-4	12979-12990	significant	_
77-5	12991-12998	results	_
77-6	12999-13002	was	_
77-7	13003-13013	restricted	_
77-8	13014-13016	to	_
77-9	13017-13020	the	_
77-10	13021-13024	PFC	_
77-11	13025-13030	given	_
77-12	13031-13034	our	_
77-13	13035-13041	strong	_
77-14	13042-13043	a	_
77-15	13044-13050	priori	_
77-16	13051-13061	hypotheses	_
77-17	13062-13071	regarding	_
77-18	13072-13085	frontolimibic	_
77-19	13086-13098	connectivity	_
77-20	13099-13100	.	_

78-1	13101-13114	Cluster-based	_
78-2	13115-13127	significance	_
78-3	13128-13140	thresholding	_
78-4	13141-13144	was	_
78-5	13145-13149	used	_
78-6	13150-13152	to	_
78-7	13153-13159	adjust	_
78-8	13160-13163	for	_
78-9	13164-13172	multiple	_
78-10	13173-13184	comparisons	_
78-11	13185-13191	within	_
78-12	13192-13195	the	_
78-13	13196-13202	search	_
78-14	13203-13209	volume	_
78-15	13210-13215	using	_
78-16	13216-13221	Monte	_
78-17	13222-13227	Carlo	_
78-18	13228-13239	simulations	_
78-19	13240-13241	(	_
78-20	13242-13244	10	_
78-21	13245-13248	000	_
78-22	13249-13259	iterations	_
78-23	13260-13261	)	_
78-24	13262-13271	performed	_
78-25	13272-13276	with	_
78-26	13277-13280	the	_
78-27	13281-13285	most	_
78-28	13286-13296	up-to-date	_
78-29	13297-13304	version	_
78-30	13305-13307	of	_
78-31	13308-13318	3dClustSim	_
78-32	13319-13320	,	_
78-33	13321-13323	an	_
78-34	13324-13334	adaptation	_
78-35	13335-13337	of	_
78-36	13338-13346	AlphaSim	_
78-37	13347-13348	(	_
78-38	13349-13354	https	_
78-39	13355-13356	:	_
78-40	13357-13418	//afni.nimh.nih.gov/pub/dist/doc/program_help/3dClustSim.html	_
78-41	13419-13420	)	_
78-42	13421-13423	in	_
78-43	13424-13428	AFNI	_
78-44	13429-13430	(	_
78-45	13431-13438	19.2.06	_
78-46	13439-13440	)	_
78-47	13441-13442	.	_

79-1	13443-13446	The	_
79-2	13447-13452	mixed	_
79-3	13453-13468	autocorrelation	_
79-4	13469-13477	function	_
79-5	13478-13481	was	_
79-6	13482-13490	utilized	_
79-7	13491-13493	to	_
79-8	13494-13498	give	_
79-9	13499-13501	an	_
79-10	13502-13510	accurate	_
79-11	13511-13521	estimation	_
79-12	13522-13524	of	_
79-13	13525-13537	non-Gaussian	_
79-14	13538-13543	noise	_
79-15	13544-13553	structure	_
79-16	13554-13555	.	_

80-1	13556-13557	A	_
80-2	13558-13564	family	_
80-3	13565-13569	wise	_
80-4	13570-13575	error	_
80-5	13576-13586	correction	_
80-6	13587-13589	at	_
80-7	13590-13591	α	_
80-8	13592-13593	<	_
80-9	13594-13598	0.05	_
80-10	13599-13602	was	_
80-11	13603-13611	achieved	_
80-12	13612-13615	for	_
80-13	13616-13621	voxel	_
80-14	13622-13631	threshold	_
80-15	13632-13634	of	_
80-16	13635-13636	P	_
80-17	13637-13638	<	_
80-18	13639-13643	.005	_
80-19	13644-13648	with	_
80-20	13649-13656	minimum	_
80-21	13657-13664	cluster	_
80-22	13665-13669	size	_
80-23	13670-13672	of	_
80-24	13673-13676	233	_
80-25	13677-13687	contiguous	_
80-26	13688-13694	voxels	_
80-27	13695-13696	.	_

81-1	13697-13709	Connectivity	_
81-2	13710-13719	parameter	_
81-3	13720-13729	estimates	_
81-4	13730-13734	from	_
81-5	13735-13746	8-mm-radius	_
81-6	13747-13754	spheres	_
81-7	13755-13766	surrounding	_
81-8	13767-13771	peak	_
81-9	13772-13783	activations	_
81-10	13784-13790	within	_
81-11	13791-13794	the	_
81-12	13795-13798	PFC	_
81-13	13799-13809	associated	_
81-14	13810-13814	with	_
81-15	13815-13819	BDNF	_
81-16	13820-13826	levels	_
81-17	13827-13831	were	_
81-18	13832-13836	then	_
81-19	13837-13846	extracted	_
81-20	13847-13850	for	_
81-21	13851-13858	further	_
81-22	13859-13867	analysis	_
81-23	13868-13869	.	_

82-1	13870-13872	We	_
82-2	13873-13877	next	_
82-3	13878-13886	examined	_
82-4	13887-13894	whether	_
82-5	13895-13899	BDNF	_
82-6	13900-13906	levels	_
82-7	13907-13910	and	_
82-8	13911-13914	the	_
82-9	13915-13926	significant	_
82-10	13927-13933	neural	_
82-11	13934-13942	findings	_
82-12	13943-13944	(	_
82-13	13945-13955	reactivity	_
82-14	13956-13962	and/or	_
82-15	13963-13975	connectivity	_
82-16	13976-13977	)	_
82-17	13978-13988	identified	_
82-18	13989-13994	above	_
82-19	13995-14005	correlated	_
82-20	14006-14010	with	_
82-21	14011-14021	real-world	_
82-22	14022-14030	drinking	_
82-23	14031-14040	behaviors	_
82-24	14041-14042	,	_
82-25	14043-14055	particularly	_
82-26	14056-14063	average	_
82-27	14064-14070	number	_
82-28	14071-14073	of	_
82-29	14074-14080	drinks	_
82-30	14081-14084	per	_
82-31	14085-14089	week	_
82-32	14090-14093	and	_
82-33	14094-14099	total	_
82-34	14100-14106	number	_
82-35	14107-14109	of	_
82-36	14110-14115	binge	_
82-37	14116-14124	episodes	_
82-38	14125-14127	in	_
82-39	14128-14131	the	_
82-40	14132-14136	past	_
82-41	14137-14139	60	_
82-42	14140-14144	days	_
82-43	14145-14146	.	_

83-1	14147-14149	We	_
83-2	14150-14154	also	_
83-3	14155-14163	examined	_
83-4	14164-14176	associations	_
83-5	14177-14181	with	_
83-6	14182-14185	age	_
83-7	14186-14188	of	_
83-8	14189-14192	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
83-9	14193-14198	onset	_
83-10	14199-14205	within	_
83-11	14206-14217	individuals	_
83-12	14218-14222	with	_
83-13	14223-14225	an	_
83-14	14226-14229	AUD	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
83-15	14230-14239	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
83-16	14240-14241	.	_

84-1	14242-14244	We	_
84-2	14245-14254	conducted	_
84-3	14255-14256	a	_
84-4	14257-14263	series	_
84-5	14264-14266	of	_
84-6	14267-14274	Pearson	_
84-7	14275-14276	’	_
84-8	14277-14278	s	_
84-9	14279-14291	correlations	_
84-10	14292-14299	between	_
84-11	14300-14306	plasma	_
84-12	14307-14311	BDNF	_
84-13	14312-14315	and	_
84-14	14316-14320	peak	_
84-15	14321-14332	significant	_
84-16	14333-14342	parameter	_
84-17	14343-14352	estimates	_
84-18	14353-14356	and	_
84-19	14357-14365	drinking	_
84-20	14366-14375	behaviors	_
84-21	14376-14377	.	_

85-1	14378-14379	A	_
85-2	14380-14385	total	_
85-3	14386-14388	of	_
85-4	14389-14390	9	_
85-5	14391-14403	correlations	_
85-6	14404-14408	were	_
85-7	14409-14412	run	_
85-8	14413-14414	.	_

86-1	14415-14416	A	_
86-2	14417-14418	P	_
86-3	14419-14424	value	_
86-4	14425-14435	correction	_
86-5	14436-14439	for	_
86-6	14440-14448	multiple	_
86-7	14449-14460	comparisons	_
86-8	14461-14464	was	_
86-9	14465-14468	not	_
86-10	14469-14476	applied	_
86-11	14477-14479	in	_
86-12	14480-14485	order	_
86-13	14486-14488	to	_
86-14	14489-14504	comprehensively	_
86-15	14505-14509	test	_
86-16	14510-14523	relationships	_
86-17	14524-14528	with	_
86-18	14529-14536	several	_
86-19	14537-14545	drinking	_
86-20	14546-14555	variables	_
86-21	14556-14557	(	_
86-22	14558-14562	i.e.	_
86-23	14563-14564	,	_
86-24	14565-14571	drinks	_
86-25	14572-14575	per	_
86-26	14576-14580	week	_
86-27	14581-14582	,	_
86-28	14583-14588	binge	_
86-29	14589-14597	episodes	_
86-30	14598-14599	,	_
86-31	14600-14603	and	_
86-32	14604-14607	AUD	_
86-33	14608-14611	age	_
86-34	14612-14614	of	_
86-35	14615-14620	onset	_
86-36	14621-14622	)	_
86-37	14623-14624	.	_

87-1	14625-14633	Although	_
87-2	14634-14637	the	_
87-3	14638-14642	aims	_
87-4	14643-14645	of	_
87-5	14646-14649	the	_
87-6	14650-14657	current	_
87-7	14658-14663	study	_
87-8	14664-14668	were	_
87-9	14669-14680	dimensional	_
87-10	14681-14682	,	_
87-11	14683-14695	participants	_
87-12	14696-14700	were	_
87-13	14701-14710	recruited	_
87-14	14711-14715	into	_
87-15	14716-14717	2	_
87-16	14718-14724	groups	_
87-17	14725-14726	:	_
87-18	14727-14738	individuals	_
87-19	14739-14743	with	_
87-20	14744-14747	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
87-21	14748-14751	and	_
87-22	14752-14760	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
87-23	14761-14762	.	_

88-1	14763-14772	Therefore	_
88-2	14773-14774	,	_
88-3	14775-14783	post-hoc	_
88-4	14784-14786	we	_
88-5	14787-14793	tested	_
88-6	14794-14801	whether	_
88-7	14802-14807	group	_
88-8	14808-14809	(	_
88-9	14810-14813	AUD	_
88-10	14814-14816	vs	_
88-11	14817-14824	control	_
88-12	14825-14826	)	_
88-13	14827-14836	moderated	_
88-14	14837-14840	any	_
88-15	14841-14843	of	_
88-16	14844-14847	the	_
88-17	14848-14853	above	_
88-18	14854-14866	associations	_
88-19	14867-14868	.	_

89-1	14869-14878	Similarly	_
89-2	14879-14880	,	_
89-3	14881-14884	the	_
89-4	14885-14890	study	_
89-5	14891-14899	included	_
89-6	14900-14905	males	_
89-7	14906-14909	and	_
89-8	14910-14917	females	_
89-9	14918-14921	and	_
89-10	14922-14924	we	_
89-11	14925-14934	therefore	_
89-12	14935-14943	examined	_
89-13	14944-14947	the	_
89-14	14948-14958	moderating	_
89-15	14959-14965	impact	_
89-16	14966-14968	of	_
89-17	14969-14979	biological	_
89-18	14980-14983	sex	_
89-19	14984-14985	.	_

90-1	14986-14989	For	_
90-2	14990-14994	each	_
90-3	14995-14998	set	_
90-4	14999-15001	of	_
90-5	15002-15010	analyses	_
90-6	15011-15012	(	_
90-7	15013-15014	1	_
90-8	15015-15016	:	_
90-9	15017-15021	BDNF	_
90-10	15022-15025	and	_
90-11	15026-15034	amygdala	_
90-12	15035-15045	reactivity	_
90-13	15046-15047	;	_
90-14	15048-15049	2	_
90-15	15050-15051	:	_
90-16	15052-15056	BDNF	_
90-17	15057-15060	and	_
90-18	15061-15073	amygdala-PFC	_
90-19	15074-15086	connectivity	_
90-20	15087-15088	;	_
90-21	15089-15092	and	_
90-22	15093-15094	3	_
90-23	15095-15096	:	_
90-24	15097-15109	correlations	_
90-25	15110-15114	with	_
90-26	15115-15123	drinking	_
90-27	15124-15133	behaviors	_
90-28	15134-15135	)	_
90-29	15136-15137	,	_
90-30	15138-15140	we	_
90-31	15141-15147	tested	_
90-32	15148-15151	the	_
90-33	15152-15158	impact	_
90-34	15159-15161	of	_
90-35	15162-15167	group	_
90-36	15168-15171	and	_
90-37	15172-15175	sex	_
90-38	15176-15181	using	_
90-39	15182-15194	hierarchical	_
90-40	15195-15201	linear	_
90-41	15202-15212	regression	_
90-42	15213-15218	where	_
90-43	15219-15224	group	_
90-44	15225-15226	,	_
90-45	15227-15230	sex	_
90-46	15231-15232	,	_
90-47	15233-15236	and	_
90-48	15237-15240	the	_
90-49	15241-15252	independent	_
90-50	15253-15261	variable	_
90-51	15262-15266	were	_
90-52	15267-15274	entered	_
90-53	15275-15277	in	_
90-54	15278-15282	Step	_
90-55	15283-15284	1	_
90-56	15285-15286	,	_
90-57	15287-15290	and	_
90-58	15291-15294	the	_
90-59	15295-15300	2-way	_
90-60	15301-15313	interactions	_
90-61	15314-15321	between	_
90-62	15322-15327	group	_
90-63	15328-15331	and	_
90-64	15332-15335	the	_
90-65	15336-15347	independent	_
90-66	15348-15356	variable	_
90-67	15357-15358	,	_
90-68	15359-15362	and	_
90-69	15363-15366	sex	_
90-70	15367-15370	and	_
90-71	15371-15374	the	_
90-72	15375-15386	independent	_
90-73	15387-15395	variable	_
90-74	15396-15397	,	_
90-75	15398-15402	were	_
90-76	15403-15410	entered	_
90-77	15411-15413	in	_
90-78	15414-15418	Step	_
90-79	15419-15420	2	_
90-80	15421-15422	.	_

91-1	15423-15434	Significant	_
91-2	15435-15447	interactions	_
91-3	15448-15452	were	_
91-4	15453-15464	followed-up	_
91-5	15465-15470	using	_
91-6	15471-15479	standard	_
91-7	15480-15486	simple	_
91-8	15487-15493	slopes	_
91-9	15494-15502	approach	_
91-10	15503-15504	.	_

92-1	15505-15511	Lastly	_
92-2	15512-15513	,	_
92-3	15514-15516	we	_
92-4	15517-15525	explored	_
92-5	15526-15533	whether	_
92-6	15534-15545	significant	_
92-7	15546-15553	results	_
92-8	15554-15558	were	_
92-9	15559-15567	affected	_
92-10	15568-15570	by	_
92-11	15571-15572	2	_
92-12	15573-15576	key	_
92-13	15577-15597	variables/covariates	_
92-14	15598-15599	:	_
92-15	15600-15604	time	_
92-16	15605-15606	(	_
92-17	15607-15609	in	_
92-18	15610-15614	days	_
92-19	15615-15616	)	_
92-20	15617-15624	between	_
92-21	15625-15629	BDNF	_
92-22	15630-15634	data	_
92-23	15635-15645	collection	_
92-24	15646-15649	and	_
92-25	15650-15653	the	_
92-26	15654-15658	fMRI	_
92-27	15659-15666	session	_
92-28	15667-15668	(	_
92-29	15669-15672	for	_
92-30	15673-15677	BDNF	_
92-31	15678-15684	models	_
92-32	15685-15689	only	_
92-33	15690-15691	)	_
92-34	15692-15695	and	_
92-35	15696-15704	lifetime	_
92-36	15705-15714	diagnosis	_
92-37	15715-15717	of	_
92-38	15718-15721	any	_
92-39	15722-15727	major	_
92-40	15728-15741	internalizing	_
92-41	15742-15750	disorder	_
92-42	15751-15752	(	_
92-43	15753-15759	yes/no	_
92-44	15760-15761	)	_
92-45	15762-15769	defined	_
92-46	15770-15772	as	_
92-47	15773-15778	major	_
92-48	15779-15789	depressive	_
92-49	15790-15798	disorder	_
92-50	15799-15800	,	_
92-51	15801-15807	social	_
92-52	15808-15815	anxiety	_
92-53	15816-15824	disorder	_
92-54	15825-15826	,	_
92-55	15827-15832	panic	_
92-56	15833-15841	disorder	_
92-57	15842-15843	,	_
92-58	15844-15852	specific	_
92-59	15853-15859	phobia	_
92-60	15860-15861	,	_
92-61	15862-15873	agoraphobia	_
92-62	15874-15875	,	_
92-63	15876-15887	generalized	_
92-64	15888-15895	anxiety	_
92-65	15896-15904	disorder	_
92-66	15905-15906	,	_
92-67	15907-15913	and/or	_
92-68	15914-15928	post-traumatic	_
92-69	15929-15935	stress	_
92-70	15936-15944	disorder	_
92-71	15945-15946	.	_

93-1	15947-15959	Correlations	_
93-2	15960-15964	were	_
93-3	15965-15968	run	_
93-4	15969-15971	as	_
93-5	15972-15979	partial	_
93-6	15980-15992	correlations	_
93-7	15993-16004	controlling	_
93-8	16005-16008	for	_
93-9	16009-16013	time	_
93-10	16014-16017	and	_
93-11	16018-16027	diagnosis	_
93-12	16028-16029	.	_

94-1	16030-16033	For	_
94-2	16034-16040	linear	_
94-3	16041-16051	regression	_
94-4	16052-16060	analyses	_
94-5	16061-16062	,	_
94-6	16063-16073	covariates	_
94-7	16074-16078	were	_
94-8	16079-16086	entered	_
94-9	16087-16089	in	_
94-10	16090-16094	Step	_
94-11	16095-16096	1	_
94-12	16097-16099	of	_
94-13	16100-16103	the	_
94-14	16104-16109	model	_
94-15	16110-16111	.	_

